US5455040A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anticoagulant plasma polymer-modified substrate
Assignee: Case Western Reserve University
•
Filing: 1992-11-19
•
Granted: 1995-10-03
•
Expires: 2012-11-19
Abstract
Abstract The present invention provides a method for surface modifying a substrate, such as an implant, to provide the substrate with anticoagulant activity and resistance to the deposition of plasma proteins; and the resulting substrate. The surface of the substrate is modified by first depositing a film of a plasma polymer such as plasma polymerized N-vinyl-2-pyrrolidone or allyl alochol on the surface of the substrate. Optionally, a neutral hydrophilic spacer molecule is attached to the plasma polymer. An anticoagulant, such as heparin, is attatched either directly to the substrate or indirectly to the substrate via attatchment to the spacer molecule, when such spacer molecule is present.
Inventors
- 👤 Roger E. Marchant
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 04:37
CPC Classifications
A; A61; A61L; A61L33/00; A61L33/0094; A61L33/0005; A61L33/0011; A61L33/0029
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
62 words
A method for reducing the thrombogenicity of a substrate, comprising the steps of: a. plasma polymerizing polar organic monomers onto the surface of the substrate to provide a plasma polymer film on the surface of the substrate; b. attaching an a anticoagulant, so that it is bound, directly or indirectly, to the plasma polymer film to provide a substrate having reduced thrombogenicity.
Claim 2
Independent Claim
62 words
A method for reducing the thrombogenicity of a substrate, comprising the steps of: a. plasma polymerizing polar organic monomers onto the surface of the substrate to provide a plasma polymer film on the surface of the substrate; b. attaching an a anticoagulant, so that it is bound, directly or indirectly, to the plasma polymer film to provide a substrate having reduced thrombogenicity.
Claim 3
Dependent Claim
15 words
The invention of claim 1, wherein the plasma polymer film is comprised of polymerized N-vinyl-2-pyrrolidone.
Claim 4
Dependent Claim
16 words
The invention of claim 1, wherein the plasma polymer film is comprised of polymerized allyl alcohol.
Claim 5
Dependent Claim
10 words
The invention of claim 1, wherein the anticoagulant is heparin.
Claim 6
Dependent Claim
19 words
The invention of claim 1, wherein the anticoagulant is heparin, and plasma polymer film is comprised of polymerized N-vinyl-2-pyrrolidione.
Claim 7
Dependent Claim
21 words
The invention of claim 1, wherein the anticoagulant is heparin, and the plasma polymer film is comprised of polymerized allyl alcohol.
Claim 8
Dependent Claim
26 words
The invention of claim 1, further comprising the step of attaching a spacer molecule to the plasma polymer film before the step of attaching the anticoagulant.
Claim 9
Dependent Claim
11 words
The invention of claim 7, wherein the spacer molecule is 3-aminopropyltriethoxysilane.
Claim 10
Dependent Claim
12 words
The invention of claim 7, wherein the spacer molecule is amino-terminated poly(ethyleneoxide).
Claim 11
Dependent Claim
50 words
The invention of claim 1, wherein the substrate is nonpolymeric, further comprising the step of first applying a plasma polyhexamethyldisilasane film to the substrate before the step of plasma polymermerizing the organic polar monomers onto the surface of the substrate to provide the plasma polymer film on the polyhexamethyldisilasane film.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-10-02 | 1999-04-03 | 1999-10-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-10-02 | 2003-04-03 | 2003-10-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-10-02 | 2007-04-03 | 2007-10-03 | $7700.00 | Window Closed / Lapsed |